Hangzhou AGS MedTech Co. Ltd. A Total Assets
Hangzhou AGS MedTech Co. Ltd. A total assets. Based on the latest financial reports, Hangzhou AGS MedTech Co. Ltd. A (688581) holds total assets worth CN¥2.70 Billion CNY (≈ $394.83 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Hangzhou AGS MedTech Co. Ltd. A (688581) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Hangzhou AGS MedTech Co. Ltd. A (2021–2025)
Total assets of Hangzhou AGS MedTech Co. Ltd. A from 2021 to 2025. This chart illustrates how Hangzhou AGS MedTech Co. Ltd. A's total assets have evolved over time, based on quarterly financial data. See Hangzhou AGS MedTech Co. Ltd. A (688581) share price today for real-time trading data and today's change.
Hangzhou AGS MedTech Co. Ltd. A - Asset Composition Analysis
Hangzhou AGS MedTech Co. Ltd. A Total Assets Breakdown (December 2025)
Hangzhou AGS MedTech Co. Ltd. A total assets breakdown as of December 2025. Hangzhou AGS MedTech Co. Ltd. A's total assets of CN¥2.70 Billion consist of 78.2% current assets and 21.8% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 44.0% |
| Accounts Receivable | CN¥54.41 Million | 2.0% |
| Inventory | CN¥59.65 Million | 2.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥48.45 Million | 1.8% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Hangzhou AGS MedTech Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Hangzhou AGS MedTech Co. Ltd. A current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hangzhou AGS MedTech Co. Ltd. A's current assets represent 78.2% of total assets in 2025, an increase from 76.8% in 2021.
- Cash Position: Cash and equivalents constituted 44.0% of total assets in 2025, down from 59.8% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 5.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 2.2% of total assets.
Hangzhou AGS MedTech Co. Ltd. A Competitors by Total Assets
Key competitors of Hangzhou AGS MedTech Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
GN Store Nord
CO:GN
|
Denmark | Dkr29.23 Billion |
|
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
SHG:688212
|
China | CN¥1.86 Billion |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$123.37 Million |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
VIROMED MEDICAL NA O.N.
XETRA:VME
|
Germany | €13.91 Million |
|
Affluent Medical SAS
PA:AFME
|
France | €59.84 Million |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩131.65 Billion |
Hangzhou AGS MedTech Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 17.48 | 20.59 | 22.61 |
| Quick Ratio | 17.03 | 19.93 | 22.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.97 Billion | CN¥1.81 Billion | CN¥2.04 Billion |
Hangzhou AGS MedTech Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Hangzhou AGS MedTech Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.91 |
| Latest Market Cap to Assets Ratio | 0.22 |
| Asset Growth Rate (YoY) | 5.0% |
| Total Assets | CN¥2.68 Billion |
| Market Capitalization | $587.60 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hangzhou AGS MedTech Co. Ltd. A's assets below their book value (0.22x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Hangzhou AGS MedTech Co. Ltd. A's assets grew by 5.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Hangzhou AGS MedTech Co. Ltd. A (2021–2025)
The table below shows the annual total assets of Hangzhou AGS MedTech Co. Ltd. A from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.68 Billion ≈ $391.68 Million |
+4.98% |
| 2024-12-31 | CN¥2.55 Billion ≈ $373.11 Million |
+9.38% |
| 2023-12-31 | CN¥2.33 Billion ≈ $341.11 Million |
+392.69% |
| 2022-12-31 | CN¥473.13 Million ≈ $69.23 Million |
+38.34% |
| 2021-12-31 | CN¥341.99 Million ≈ $50.04 Million |
-- |
About Hangzhou AGS MedTech Co. Ltd. A
Hangzhou AGS MedTech Co., Ltd., together with its subsidiaries, engages in the research, development, production, sale, and service of endoscopic minimally invasive diagnostic and therapeutic instruments in China and internationally. The company offers hemostasis products, including hemoclips and traction clips; biopsy products, such as disposable biopsy, swinging biopsy, and grasping forceps; an… Read more